VEA
PRVL

Virtus ETF Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Virtus ETF Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,601
Closed -$544K – 415
2020
Q4 		$544K Buy
23,601
+3,828
+19% +$48.5K 0.23% 134
2020
Q3 		$201K Sell
19,773
-2,687
-12% -$36K 0.11% 299
2020
Q2 		$335K Buy
+22,460
New +$346K 0.16% 280

Virtus ETF Advisers's PRVL Position: Q1 2021 in Review

Virtus ETF Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 23,601 shares — an estimated $544K sold.

Virtus ETF Advisers first reported a position in PRVL in Q2 2020 and held it in 3 quarters. The position peaked at $544K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Virtus ETF Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 23,601 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $544K.
  • Virtus ETF Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Virtus ETF Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $544K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Virtus ETF Advisers's 13F filing for Q1 2021, filed 17 May 2021.